Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger
Overview
Authors
Affiliations
Background: Young age at breast cancer diagnosis has been associated with increased risk of recurrence and mortality. We reevaluated this assumption in a large, modern cohort of women diagnosed with breast cancer at age ≤40 years.
Methods: We identified women with breast cancer at age ≤40 years at a single institution from 1996-2008. We assessed locoregional recurrence (LRR), distant recurrence, disease-free survival (DFS), and overall survival (OS), and correlated patient and tumor characteristics with outcomes.
Results: We identified 584 women aged ≤40 years with breast cancer. Median age was 37 years, and median follow-up was 124 months; 61.5 % were stages 0-I and 38.5 % were stages II-III. Overall, 57.4 % had lumpectomies and 42.5 % mastectomies. DFS was 93 % at 5 years and 84.5 % at 10 years. OS was 93 % at 5 years and 86.5 % at 10 years. On multivariate analysis, worse DFS was associated with positive nodes (p = 0.002); worse OS was associated with larger tumor size (p = 0.042). When stratified by lumpectomy versus mastectomy, there were no significant differences in survival or recurrence. For lumpectomy patients, DFS was 96 % at 5 years and 88 % at 10 years; OS was 96 % at 5 years and 89 % at 10 years. For mastectomy patients, DFS was 89.5 % at 5 years and 79 % at 10 years; OS was 90 % at 5 years and 83 % at 10 years. Lumpectomy LRR rates were 1 % at 5 years and 4 % at 10 years. Mastectomy LRR rates were 3.5 % at 5 years and 8.7 % at 10 years.
Conclusions: Outcomes for women with breast cancer at age ≤40 years have improved. Lumpectomy recurrence rates are low, suggesting that lumpectomy is oncologically safe for young breast cancer patients.
Georgescu R, Tutuianu F, Bauer O, Toganel A, Benedek Z, Darii E Cancers (Basel). 2024; 16(17).
PMID: 39272788 PMC: 11394422. DOI: 10.3390/cancers16172930.
Boutrus R, Abdelazim Y, Mohammed T, Bayomy M, Ibraheem M, Hussein A BMC Cancer. 2024; 24(1):599.
PMID: 38760780 PMC: 11100067. DOI: 10.1186/s12885-024-12325-3.
Tan M, Sitoh Y Gland Surg. 2023; 12(4):535-547.
PMID: 37200923 PMC: 10186170. DOI: 10.21037/gs-22-609.
The role of tumor phenotype in the surgical treatment of early-stage breast cancer.
Rooney M, Thomas S, Taskindoust M, Greenup R, Rosenberger L, Hwang E Am J Surg. 2022; 225(1):84-92.
PMID: 36180300 PMC: 9912362. DOI: 10.1016/j.amjsurg.2022.09.029.
Kumilau R, Hayati F, Liew J, Sharif S, Nik Lah N Ann Med Surg (Lond). 2022; 81:104560.
PMID: 36147066 PMC: 9486850. DOI: 10.1016/j.amsu.2022.104560.